questionsmedicales.fr
Maladies de l'appareil digestif
Tumeurs de l'appareil digestif
Tumeurs des voies biliaires
Tumeurs des voies biliaires : Questions médicales fréquentes
Termes MeSH sélectionnés :
Neoplasm Recurrence, Local
Diagnostic
5
Tumeurs des voies biliaires
Biopsie
Imagerie médicale
Marqueurs tumoraux
Tests de fonction hépatique
Tumeurs des voies biliaires
Imagerie par résonance magnétique
Tumeurs des voies biliaires
Diagnostic
Cholangiographie
Tumeurs des voies biliaires
Diagnostic
Symptômes
Tumeurs des voies biliaires
Jaunisse
Symptômes
5
Symptômes
Tumeurs des voies biliaires
Perte de poids
Jaunisse
Tumeurs des voies biliaires
Obstruction biliaire
Démangeaisons
Tumeurs des voies biliaires
Bile
Nausées
Tumeurs des voies biliaires
Système digestif
Douleur abdominale
Tumeurs des voies biliaires
Symptômes
Prévention
5
Prévention
Hépatite
Alcool
Facteurs de risque
Alcoolisme
Produits chimiques
Alimentation
Prévention
Maladies hépatiques
Infections chroniques
Hépatite B
Hépatite C
Tabagisme
Facteurs de risque
Cancers
Traitements
5
Chirurgie
Chimiothérapie
Tumeurs des voies biliaires
Chirurgie
Tumeurs des voies biliaires
Traitement
Chimiothérapie
Tumeurs des voies biliaires
Traitement
Radiothérapie
Tumeurs des voies biliaires
Traitement
Traitements ciblés
Tumeurs des voies biliaires
Oncologie
Complications
5
Complications
Obstruction biliaire
Métastase
Obstruction biliaire
Complications
Infections hépatiques
Infections
Complications
Tumeurs des voies biliaires
Métastases
Complications
Traitement
Prévention
Complications
Suivi médical
Facteurs de risque
5
Facteurs de risque
Hépatite chronique
Toxines
Âge
Facteurs de risque
Tumeurs des voies biliaires
Maladies hépatiques
Cirrhose
Facteurs de risque
Arsenic
Facteurs de risque
Cancers
Antécédents familiaux
Facteurs de risque
Cancers
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Tumeurs des voies biliaires : Questions médicales les plus fréquentes",
"headline": "Tumeurs des voies biliaires : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Tumeurs des voies biliaires : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-20",
"dateModified": "2025-04-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Tumeurs des voies biliaires"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs de l'appareil digestif",
"url": "https://questionsmedicales.fr/mesh/D004067",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs de l'appareil digestif",
"code": {
"@type": "MedicalCode",
"code": "D004067",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C06.301"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Tumeurs des canaux biliaires",
"alternateName": "Bile Duct Neoplasms",
"url": "https://questionsmedicales.fr/mesh/D001650",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs des canaux biliaires",
"code": {
"@type": "MedicalCode",
"code": "D001650",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C06.301.120.250"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Tumeurs du cholédoque",
"alternateName": "Common Bile Duct Neoplasms",
"url": "https://questionsmedicales.fr/mesh/D003138",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs du cholédoque",
"code": {
"@type": "MedicalCode",
"code": "D003138",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C06.301.120.250.250"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Tumeurs de la vésicule biliaire",
"alternateName": "Gallbladder Neoplasms",
"url": "https://questionsmedicales.fr/mesh/D005706",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs de la vésicule biliaire",
"code": {
"@type": "MedicalCode",
"code": "D005706",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C06.301.120.401"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs des voies biliaires",
"alternateName": "Biliary Tract Neoplasms",
"code": {
"@type": "MedicalCode",
"code": "D001661",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yasuni Nakanuma",
"url": "https://questionsmedicales.fr/author/Yasuni%20Nakanuma",
"affiliation": {
"@type": "Organization",
"name": "Department of Diagnostic Pathology, Shizuoka Cancer Center, Shizuoka, Japan; Department of Diagnostic Pathology, Fukui Prefecture Saiseikai Hospital, Japan. Electronic address: nakanumayasu@gmail.com."
}
},
{
"@type": "Person",
"name": "Takashi Sugino",
"url": "https://questionsmedicales.fr/author/Takashi%20Sugino",
"affiliation": {
"@type": "Organization",
"name": "Department of Diagnostic Pathology, Shizuoka Cancer Center, Shizuoka, Japan."
}
},
{
"@type": "Person",
"name": "Yasunori Sato",
"url": "https://questionsmedicales.fr/author/Yasunori%20Sato",
"affiliation": {
"@type": "Organization",
"name": "Department of Human Pathology, Kanazawa University School of Medicine, Kanazawa, Japan."
}
},
{
"@type": "Person",
"name": "Hans-Olov Adami",
"url": "https://questionsmedicales.fr/author/Hans-Olov%20Adami",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden."
}
},
{
"@type": "Person",
"name": "Gary E Fraser",
"url": "https://questionsmedicales.fr/author/Gary%20E%20Fraser",
"affiliation": {
"@type": "Organization",
"name": "School of Public Health, Loma Linda University, Loma Linda, California."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Classification of Local Recurrence After Nipple-Sparing Mastectomy Based on Location: The Features of Nipple-Areolar Recurrence Differ from Those of Other Local Recurrences.",
"datePublished": "2022-11-13",
"url": "https://questionsmedicales.fr/article/36371582",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1245/s10434-022-12760-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Feasibility of local therapy for recurrent pancreatic cancer.",
"datePublished": "2022-05-24",
"url": "https://questionsmedicales.fr/article/35641368",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.pan.2022.05.004"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ultrasound Assessment of Skin Tumors Local Recurrence.",
"datePublished": "2023-05-17",
"url": "https://questionsmedicales.fr/article/37195073",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jum.16255"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pathological determinants of outcome following resection of locally advanced or locally recurrent rectal cancer.",
"datePublished": "2023-06-26",
"url": "https://questionsmedicales.fr/article/37442715",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejso.2023.06.023"
}
},
{
"@type": "ScholarlyArticle",
"name": "Intraparenchymal metastases as a cause for local recurrence of pancreatic cancer.",
"datePublished": "2022-11-21",
"url": "https://questionsmedicales.fr/article/36371607",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/his.14839"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies de l'appareil digestif",
"item": "https://questionsmedicales.fr/mesh/D004066"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs de l'appareil digestif",
"item": "https://questionsmedicales.fr/mesh/D004067"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs des voies biliaires",
"item": "https://questionsmedicales.fr/mesh/D001661"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Tumeurs des voies biliaires - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Tumeurs des voies biliaires",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-30",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Tumeurs des voies biliaires",
"description": "Comment diagnostique-t-on une tumeur des voies biliaires ?\nQuels tests sanguins sont utiles pour le diagnostic ?\nQuelle est l'importance de l'IRM dans le diagnostic ?\nPeut-on utiliser la cholangiographie pour le diagnostic ?\nQuels symptômes peuvent alerter sur une tumeur ?",
"url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Neoplasm+Recurrence,+Local#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Tumeurs des voies biliaires",
"description": "Quels sont les symptômes courants des tumeurs biliaires ?\nLa jaunisse est-elle un symptôme fréquent ?\nPeut-on avoir des démangeaisons avec une tumeur biliaire ?\nLes nausées sont-elles un symptôme associé ?\nComment la douleur abdominale se manifeste-t-elle ?",
"url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Neoplasm+Recurrence,+Local#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Tumeurs des voies biliaires",
"description": "Peut-on prévenir les tumeurs des voies biliaires ?\nQuels facteurs de risque sont évitables ?\nL'alimentation joue-t-elle un rôle ?\nLes infections chroniques augmentent-elles le risque ?\nLe tabagisme est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Neoplasm+Recurrence,+Local#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Tumeurs des voies biliaires",
"description": "Quels sont les traitements possibles pour ces tumeurs ?\nLa chirurgie est-elle toujours possible ?\nQuand la chimiothérapie est-elle recommandée ?\nLa radiothérapie est-elle efficace ?\nY a-t-il des traitements ciblés disponibles ?",
"url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Neoplasm+Recurrence,+Local#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Tumeurs des voies biliaires",
"description": "Quelles complications peuvent survenir ?\nL'obstruction biliaire est-elle grave ?\nLes infections sont-elles fréquentes ?\nQuelles sont les conséquences des métastases ?\nPeut-on prévenir les complications ?",
"url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Neoplasm+Recurrence,+Local#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Tumeurs des voies biliaires",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de tumeurs biliaires ?\nLes maladies hépatiques augmentent-elles le risque ?\nL'exposition à l'arsenic est-elle un risque ?\nLes antécédents familiaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Neoplasm+Recurrence,+Local#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on une tumeur des voies biliaires ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par imagerie (échographie, IRM) et biopsie."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utiles pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent les marqueurs tumoraux comme l'ACE et les tests de fonction hépatique."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de l'IRM dans le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM permet de visualiser les tumeurs et d'évaluer leur extension."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser la cholangiographie pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la cholangiographie permet de visualiser les voies biliaires et détecter des obstructions."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent alerter sur une tumeur ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs abdominales, jaunisse, et démangeaisons peuvent indiquer une tumeur."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants des tumeurs biliaires ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleur abdominale, jaunisse, et perte de poids."
}
},
{
"@type": "Question",
"name": "La jaunisse est-elle un symptôme fréquent ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la jaunisse est fréquente et résulte d'une obstruction des voies biliaires."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des démangeaisons avec une tumeur biliaire ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les démangeaisons peuvent survenir en raison de l'accumulation de bile."
}
},
{
"@type": "Question",
"name": "Les nausées sont-elles un symptôme associé ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les nausées peuvent être présentes en raison de l'irritation du système digestif."
}
},
{
"@type": "Question",
"name": "Comment la douleur abdominale se manifeste-t-elle ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "La douleur est souvent localisée dans la partie supérieure droite de l'abdomen."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les tumeurs des voies biliaires ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais éviter l'hépatite et l'alcool peut aider."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont évitables ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'alcoolisme et l'exposition à des produits chimiques sont des facteurs évitables."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine peut réduire le risque de maladies hépatiques, mais pas spécifiquement."
}
},
{
"@type": "Question",
"name": "Les infections chroniques augmentent-elles le risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les infections chroniques comme l'hépatite B et C augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est associé à un risque accru de plusieurs cancers, y compris biliaires."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements possibles pour ces tumeurs ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chirurgie, la chimiothérapie et la radiothérapie."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle toujours possible ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la chirurgie dépend de la taille et de l'emplacement de la tumeur."
}
},
{
"@type": "Question",
"name": "Quand la chimiothérapie est-elle recommandée ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chimiothérapie est souvent utilisée pour les tumeurs avancées ou inopérables."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle efficace ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La radiothérapie peut soulager les symptômes et est utilisée en complément."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements ciblés disponibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements ciblés peuvent être utilisés selon le type de tumeur."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'obstruction biliaire, l'infection et la métastase."
}
},
{
"@type": "Question",
"name": "L'obstruction biliaire est-elle grave ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des douleurs sévères et des infections hépatiques."
}
},
{
"@type": "Question",
"name": "Les infections sont-elles fréquentes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les infections peuvent survenir en raison de l'obstruction des voies biliaires."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences des métastases ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les métastases peuvent affecter d'autres organes et compliquer le traitement."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par un suivi médical régulier."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, l'hépatite chronique et l'exposition à des toxines."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de tumeurs biliaires ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente avec l'âge, surtout après 50 ans."
}
},
{
"@type": "Question",
"name": "Les maladies hépatiques augmentent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies hépatiques chroniques comme la cirrhose augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'exposition à l'arsenic est-elle un risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à l'arsenic est associée à un risque accru de cancers biliaires."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancers peuvent augmenter le risque."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 14/04/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Diagnostic Pathology, Shizuoka Cancer Center, Shizuoka, Japan; Department of Diagnostic Pathology, Fukui Prefecture Saiseikai Hospital, Japan. Electronic address: nakanumayasu@gmail.com.
Publications dans "Tumeurs des voies biliaires" :
3 publications dans cette catégorie
Affiliations :
Department of Diagnostic Pathology, Shizuoka Cancer Center, Shizuoka, Japan.
Publications dans "Tumeurs des voies biliaires" :
3 publications dans cette catégorie
Affiliations :
Department of Human Pathology, Kanazawa University School of Medicine, Kanazawa, Japan.
Publications dans "Tumeurs des voies biliaires" :
3 publications dans cette catégorie
Affiliations :
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Department of Health Management and Health Economics, University of Oslo, Oslo, Norway.
Publications dans "Tumeurs des voies biliaires" :
3 publications dans cette catégorie
Affiliations :
School of Public Health, Loma Linda University, Loma Linda, California.
Publications dans "Tumeurs des voies biliaires" :
3 publications dans cette catégorie
Affiliations :
Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
Publications dans "Tumeurs des voies biliaires" :
3 publications dans cette catégorie
Affiliations :
Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia.
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia.
Publications dans "Tumeurs des voies biliaires" :
3 publications dans cette catégorie
Affiliations :
Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
Publications dans "Tumeurs des voies biliaires" :
3 publications dans cette catégorie
Affiliations :
School of Public Health, Loma Linda University, Loma Linda, California.
Publications dans "Tumeurs des voies biliaires" :
3 publications dans cette catégorie
Affiliations :
Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
Publications dans "Tumeurs des voies biliaires" :
3 publications dans cette catégorie
Affiliations :
Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia.
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia.
Publications dans "Tumeurs des voies biliaires" :
3 publications dans cette catégorie
Affiliations :
Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina.
Publications dans "Tumeurs des voies biliaires" :
3 publications dans cette catégorie
Affiliations :
Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
Publications dans "Tumeurs des voies biliaires" :
3 publications dans cette catégorie
Affiliations :
Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina.
Publications dans "Tumeurs des voies biliaires" :
3 publications dans cette catégorie
Affiliations :
Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Publications dans "Tumeurs des voies biliaires" :
3 publications dans cette catégorie
Affiliations :
Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
Publications dans "Tumeurs des voies biliaires" :
3 publications dans cette catégorie
Affiliations :
Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
Publications dans "Tumeurs des voies biliaires" :
3 publications dans cette catégorie
Affiliations :
Behavioral and Epidemiology Research Group, American Cancer Society, Inc., Atlanta, Georgia.
Publications dans "Tumeurs des voies biliaires" :
3 publications dans cette catégorie
Affiliations :
Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
Publications dans "Tumeurs des voies biliaires" :
2 publications dans cette catégorie
Affiliations :
Department of Diagnostic Pathology, Shizuoka Cancer Center, Shizuoka, Japan.
Publications dans "Tumeurs des voies biliaires" :
Little information is available about the clinical and pathologic characteristics of local recurrence (LR) after nipple-sparing mastectomy according to the locations of LR....
This study classified 99 patients into the following two groups according to the location of LR after nipple-sparing mastectomy: nipple-areolar recurrence (NAR) group and other locations of LR (oLR) g...
For about half of the patients (44.4 %) with NAR, the primary cancer was estrogen receptor (ER)-negative and human epidermal growth factor receptor 2 (HER2)-positive. Conversely, in most of the patien...
This multi-institutional retrospective study demonstrated that the features of NAR, such as the characteristics of the primary and recurrent tumors and the prognostic factors after LR resection, were ...
Despite advances in perioperative management, recurrence after curative pancreatectomy is a critical issue in the treatment of pancreatic ductal adenocarcinoma (PDAC). The significance of local therap...
We reviewed the medical records of patients with PDAC who underwent curative resection at our institution between January 2009 and December 2019. We examined the patterns of relapse and assessed the c...
A total of 246 patients with PDAC who underwent R0 or R1 resection were included in this study. The 3-year overall survival (OS) rate was 39.8%, and the 1-year recurrence-free survival rate was 51.2% ...
Our results suggest that a multimodal approach may improve the clinical outcomes of patients with recurrent PDAC....
Skin cancer may recur at or around the surgical site despite wide excisions. Prompt clinical and sonographic detection of local recurrence is important since subjects with relapsing melanomas or nonme...
Pathological factors that influence and predict survival following pelvic exenteration (PE) for locally advanced (LARC) or locally recurrent rectal cancer (LRRC), especially LRRC, remain poorly unders...
A retrospective cohort study was performed for all patients undergoing a curative PE for LARC or LRRC between 2008 and 2021 at a tertiary referral UK specialist colorectal hospital. Cox regression ana...
388 patients were included in the analysis with 256 resections for LARC and 132 for LRRC. 62.4% of patients were male with a median age of 59 years (IQR 49-67). 247 (64%) partial pelvic exenterations ...
A positive resection margin and poorly differentiated tumours are significant negative prognostic markers for survival and recurrence in LARC. The results of this study support the need to look for al...
Using CODA, a technique for three-dimensional reconstruction of large tissues, Kiemen et al. report observation of a microscopic focus of pancreatic cancer found in the vasculature of grossly normal h...
The initial approach to the treatment of desmoid tumors has changed from surgical resection to watchful waiting. However, surgery is still sometimes considered for some patients, and it is likely that...
We sought to explore whether a combined molecular and clinical prognostic model for relapse in patients with desmoid tumors treated with surgery would allow us to identify patients who might do well w...
This was a retrospective, single-center study of 107 patients with desmoid tumors who were surgically treated between January 1980 and December 2015, with a median follow-up of 106 months (range 7 to ...
The multivariable analysis showed that S45F mutations (hazard ratio 5.25 [95% confidence interval 2.27 to 12.15]; p < 0.001) and tumor in the extremities (HR 3.15 [95% CI 1.35 to 7.33]; p = 0.008) wer...
CTNNB1 S45F mutations combined with other clinical variables are a potential prognostic biomarker associated with the risk of relapse in patients with desmoid tumors. The developed nomogram is simple ...
Level III, therapeutic study....
A first local recurrence is common after resection or radiotherapy for brain metastasis (BM). However, patients with BMs can develop multiple local recurrences over time. Published data on second loca...
Patients were identified from a database at Brigham and Women's Hospital in Boston. Hazard ratios and 95% confidence intervals for predictors of a second local recurrence were computed using a Cox pro...
Of 170 identified surgically treated first locally recurrent lesions, 74 (43.5%) progressed to second locally recurrent lesions at a median of 7 months after craniotomy. Subtotal resection of the firs...
A second local recurrence occurred after 43.5% of craniotomies for first recurrent lesions. Subtotal resection and infratentorial location were the strongest risk factors for worse second local recurr...
The current study was undertaken to provide more detailed prognostic models for early prediction of local recurrences and local recurrence free survival (RFS) using different radiologic and pathologic...
One hundred patients with locally advanced rectal carcinomas decided to receive neoadjuvant CRT were retrospectively recruited, Hazard ratios (HR) were determined in the two cox regression models and ...
HR of 1st group of models: T+N, T+N+G, T+N+G+S, T+N+G+S+PNI, and T+N+G+S+PNI+R were summated and categorized into scores, these scores were significantly correlated with the risk of recurrence (Somer'...
We propose that the addition of biologic factors to staging of rectal cancer provide precise stratification and association with local recurrences in patients received preoperative CRT....
This study aims to identify prognostic factors and define the best extent of surgery for optimizing treatment of local recurrence (LR) following colorectal cancer (CRC)....
An institutional database of consecutive patients who underwent radical resection (R0/R1) of LR following CRC was analyzed prospectively from 2010 to 2021 at one tertiary cancer center....
In this study, 75 patients were included with LR following CRC and analyzed. Patients were categorized as compartmental resections (CompRe) (n = 47) if all adjacent organs were systematically removed,...
Complete compartmental surgery is safe and improves local control. Optimal LR resection needs to remove all contiguous organs, with or without tumor involvement....
RET-fused mesenchymal neoplasms mostly affect the soft tissue of paediatric patients. Given their responsiveness to selective RET inhibitors, it remains critical to identify those extraordinary cases ...
Clinicopathological features were assessed and partner agnostic targeted next-generation sequencing on clinically validated platforms were performed. The patients were 18, 53, and 55 years old and inc...
Our study expands the clinicopathological and genetic spectrum of mesenchymal neoplasms associated with RET fusions....